Board approves Q2 results; in-principle nod to raise up to ₹68 crore for proposed 60% acquisition
Board approved unaudited Q2/H1 FY27 results; limited review finds no material misstatement.
By ScoutQuest · · 3 min read
- Q2 FY27 Revenue from Operations
- 15.80 lakh (quarter ended 30 September 2026, standalone, unaudited)
- Q2 FY27 Loss for the Period
- (51.40) lakh (quarter ended 30 September 2026, standalone, unaudited)
- Approved Fund Raise
- up to ₹68 crore in one or more tranches for proposed acquisition of 60% of Meyonex Pharmaceuticals Ltd
Board meeting outcome, 4 November 2026
Tavexia Lifecare's Board met on Wednesday, 04 November 2026 and approved the unaudited standalone and consolidated financial results for the quarter and half year ended 30 September 2026. Statutory auditors Devam & Associates LLP issued limited review reports on both sets of results, stating that nothing came to their attention that causes them to believe the statements contain a material misstatement. The review reports note that a review is substantially less in scope than an audit.
Other items taken on record
- Statement of deviation(s) or variation(s) on the use of proceeds from the objects stated in the rights issue offer document.
- Change of Registrar and Share Transfer Agent from Niche Technologies Pvt. Ltd to Skyline Financial Services Pvt. Ltd. The stated reason is Skyline's technologically advanced infrastructural framework, capacity to align with share registry activities and wider reach to the shareholders' base. Niche continues as RTA until data transition, shifting of electronic connectivity and confirmations from NSDL and CDSL are completed; the effective date will be intimated separately.
Fund raising proposal
- The Board accorded its in-principle approval to raise funds through a preferential issue of securities, a rights issue of equity shares or any other permissible mode, in one or more tranches.
- Aggregate amount: not exceeding ₹68 crore (Rupees Sixty-Eight Crores Only).
- Use of money: to finance the proposed acquisition of 60% of the equity share capital of Meyonex Pharmaceuticals Limited, approved by the Board at its meeting on 07 October 2026.
- Executive Directors authorised to appoint consultants, professionals, intermediaries, valuers and other experts to evaluate and recommend the most appropriate mode and type of securities issuance.
- The final decision on mode, structure, terms and conditions will be considered and approved at a subsequent Board meeting, and additional disclosure will be given at that stage.
Standalone results, quarter ended 30 September 2026 (figures in lakh as printed)
- Revenue from operations: 15.80
- Total expenses: 67.87
- Profit before tax: (52.07)
- Loss for the period: (51.40)
Standalone results, half year ended 30 September 2026 (figures in lakh as printed)
- Revenue from operations: 39.20
- Total expenses: 128.64
- Profit before tax: (89.44)
- Loss for the period: (73.75)
Balance sheet snapshot as at 30 September 2026 (standalone, figures in lakh as printed)
- Total assets: 4,864.57
- Paid-up equity share capital: 3,836.01, with face value of ₹1.00 per equity share
- Short-term borrowings: 414.18
- Inventories: 908.27
What investors can watch
- The fund raise is at an in-principle stage. The ceiling of ₹68 crore is fixed, while the instrument, price and terms are yet to be decided by the Board. A preferential issue and a rights issue treat existing shareholders differently, and the update leaves the choice open.
- The money is earmarked for a 60% stake in Meyonex Pharmaceuticals; the acquisition was approved by the Board on 07 October 2026 and this fund raise is the financing step for it.
- The quarterly and half-year figures are unaudited and reviewed, and the standalone profit and loss account for the half year shows a loss for the period.
Also from Tavexia Lifecare
Consolidated results for the 30.09.2026 Unaudited
4 Nov 2026
Board gives in-principle nod to raise up to Rs. 68 crore for 60% Meyonex stake; H1 shows a loss
4 Nov 2026
Board meet on 4 November 2026 to consider Q2 results, RTA change and initial fund-raise proposal
30 Oct 2026
More numbers
- Proposed fund raising, aggregate amount₹68,00,00,000/-
- Proposed acquisition: stake in Meyonex Pharmaceuticals Ltd60%
- Revenue from operations, quarter ended 30.09.2026 (standalone)15.80 (In Lacs)
- Loss for the period, quarter ended 30.09.2026 (standalone)(51.40) (In Lacs)
- Revenue from operations, half year ended 30.09.2026 (standalone)39.20 (In Lacs)
- Loss for the period, half year ended 30.09.2026 (standalone)(73.75) (In Lacs)
- Paid-up equity share capital as at 30.09.20263,836.01 (In Lacs)
- Total expenses, half year ended 30.09.2026 (standalone)128.64 (In Lacs)
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.